{"prompt": "['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', '(from the time the subject signs informed consent until 28 days after the last dose of IP) and all', 'SAEs made known to the Investigator at any time following the protocol-required reporting', 'period or after end of study. . Serious adverse events occurring prior to treatment (after signing', 'the ICF) are to be collected/recorded/reported.', 'Where required by local legislation, the Investigator is responsible for informing the Institutional', 'Review Board/Ethics Committee (IRB/EC) of the SAE and providing them with all relevant', 'initial and follow-up information about the event. The Investigator must keep copies of all SAE', 'information on file including correspondence with Amgen and the IRB/EC.', 'Serious Adverse Event Reporting transmitted via paper Serious Adverse Event Report', 'Form:', 'Facsimile transmission of the Serious Adverse Event Report Form is the preferred', 'method to transmit this information. If facsimile is unavailable, the email method to', 'transmit this information is acceptable (refer to Appendix S).', 'In rare circumstances and in the absence of facsimile equipment, this form may be sent', 'via email, or notification by telephone is acceptable with a copy of the Serious Adverse', 'Event Report Form in English language sent by overnight mail or courier service.', 'Initial notification via telephone does not replace the need for the investigator to', 'complete and sign the Serious Adverse Event Report Form within the designated', 'reporting timeframes.', 'Once the study has ended, serious adverse events (regardless of causality) should be', 'reported to Amgen Global Patient Safety if the investigator becomes aware of them and', 'may use the paper Serious Adverse Event Report Form (refer to Appendix S).', '10.5.1.', 'Safety Queries', 'Queries pertaining to SAEs will be communicated/generated from Amgen Global Patient Safety', \"to the site via Amgen's safety query paper process or other appropriate method.\", '10.6.', 'Expedited Reporting of Adverse Events', 'For the purpose of regulatory reporting, Amgen Global Patient Safety will determine the', \"expectedness of events suspected of being related to apremilast based on the Investigator's\", 'Brochure. For countries within the European Economic Area (EEA), Amgen or its authorized', 'representative will report in an expedited manner to Regulatory Authorities and Ethics', 'Committees concerned, suspected unexpected serious adverse reactions (SUSARs) in accordance', 'with Directive 2001/20/EC and the Detailed Guidance on collection, verification and', 'presentation of adverse reaction reports arising from clinical trials on investigational products for', 'human use (ENTR/CT3) and also in accordance with country-specific requirements.', 'Amgen or its authorized representative shall notify the Investigator of the following information:', 'Any AE suspected of being related to the use of IP in this study or in other studies', 'that is both serious and unexpected (ie, SUSAR).', 'Any finding from tests in laboratory animals that suggests a significant risk for', 'human subjects including reports of mutagenicity, teratogenicity, or carcinogenicity.', 'Confidential and Proprietary', '57', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']['Apremilast', 'Protocol CC-10004-PSOR-020', 'Amgen Inc.', 'Where required by local legislation, the Investigator shall notify his/her IRB/EC promptly of', 'these new serious and unexpected AE(s) or significant risks to subjects.', 'The Investigator must keep copies of all pertinent safety information on file including', 'correspondence with Amgen and the IRB/EC. (See Section 14.3 for record retention', 'information).', 'Amgen Global Patient Safety Contact Information (fax/email):', \"For Amgen Global Patient Safety contact information, please refer to your site's paper Serious\", 'Adverse Event Report Form, paper Pregnancy Notification Form and/or paper Lactation', 'Notification Form (Appendix S, Appendix T, Appendix U).', 'Confidential and Proprietary', '58', 'CC-10004-PSOR-020 Amendment 3 FINAL: 01 May 2020', 'EDMS Doc. Number: 24684941 - 22835610']\n\n###\n\n", "completion": "END"}